Grasse BIOTECH

grassebiotech.fr

Grasse BIOTECH - Hotel of innovation companies and support of startups in the field of cosmetologies, biotechnologies, health, life sciences and scientific research and analysis activities of the Pays de Grasse, benefits from added value linked to a privileged project accelerator environment. On the ArômaGrasse Business Park where are hosted more than 15 companies such as: Perfume Cosmetic World, TOMCOS, SelectArôme ... mostly PASS (Perfumes, Aromas, Scents, Flavors). In connection with Espace Jacques-Louis Lions where are located: o the InnovaGrasse business incubator, o the University of Nice Sophia-Antipolis: training in fine chemistry master 2 FOQUAL, its students, professors and researchers in a place conducive to teaching and research (classrooms, laboratories, exchange rooms ...), o Technological and regulatory resources represented by the PASS Competitiveness Cluster and its partnership analytical chemistry platform, whose objective is to strengthen R & D by bringing researchers from the academic sector and the private sector together in a single location (certification and authentication). ingredients). In an already existing network of support for creation and innovation, Grasse BIOTECH thus makes it possible to cover the entire chain of support to businesses: from creation to their long-term presence on the territory of the Communauté d'Agglomération du Pays de Grasse. Grasse BIOTECH is funded with the support of the European Union with the European Regional Development Fund, the Regional Council PACA and the Departmental Council of the Alpes-Maritimes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

ENZYCHEM LIFESCIENCES ANNOUNCES FORMATION OF CORPORATE ADVISORY COMMITTEE

Enzychem Lifesciences | March 03, 2022

news image

Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18. After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation&ndash...

Read More

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More

MEDICAL

ALLIGATOR BIOSCIENCE ANNOUNCES IND APPROVAL FOR CD40 TARGETING ANTIBODY MITAZALIMAB

Alligator Bioscience | December 07, 2020

news image

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...

Read More

MEDICAL

LILLY, VIR BIOTECHNOLOGY AND GSK COLLABORATES TO EVALUATE A COMBINATION OF TWO COVID-19 THERAPIES IN LOW-RISK PATIENTS

Lilly | January 28, 2021

news image

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...

Read More
news image

CELL AND GENE THERAPY

ENZYCHEM LIFESCIENCES ANNOUNCES FORMATION OF CORPORATE ADVISORY COMMITTEE

Enzychem Lifesciences | March 03, 2022

Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18. After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation&ndash...

Read More
news image

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More
news image

MEDICAL

ALLIGATOR BIOSCIENCE ANNOUNCES IND APPROVAL FOR CD40 TARGETING ANTIBODY MITAZALIMAB

Alligator Bioscience | December 07, 2020

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...

Read More
news image

MEDICAL

LILLY, VIR BIOTECHNOLOGY AND GSK COLLABORATES TO EVALUATE A COMBINATION OF TWO COVID-19 THERAPIES IN LOW-RISK PATIENTS

Lilly | January 28, 2021

Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...

Read More